Eli Lilly Shares Positive Omvoh Data from VIVID-2 Crohn’s Study

Eli Lilly Shares Positive Omvoh Data from VIVID-2 Crohn’s Study

Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of continuous treatment with Omvoh (mirikizumab-mrkz) achieved long-term clinical and endoscopic outcomes, including those (43.8%) with previous biologic failure. Data from this study presented at the Crohn's and Colitis Congress (CCC), being held from February 6-8, 2025 in San Francisco.

Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.

""Many people living with Crohn's disease have tried available therapies without success or have experienced a loss of efficacy with their treatment,"" said Edward Barnes, M.D., MPH, Associate Professor of Medicine in the Division of Gastroenterology & Hepatology, co-director of the Multidisciplinary Inflammatory Bowel Diseases Center at the University of North Carolina at Chapel Hill. ""These positive, multi-year data can give health care providers confidence that Omvoh may help their patients achieve and maintain long-term outcomes, including intestinal healing.""

Participants randomized to Omvoh in the phase 3 VIVID-1 study who achieved endoscopic response after one year of treatment continued Omvoh maintenance treatment in VIVID-2. The following results were achieved based upon observed case analysis after two years of continuous treatment, including one year during VIVID-1:

•    Among patients who were in clinical remission at one year in VIVID-1, 92.9% maintained clinical remission at two years as measured by Crohn's Disease Activity Index (CDAI).
•    Among patients treated in VIVID-2, 87.6% maintained endoscopic response, defined by visible healing of the intestinal lining and measured by a =50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) total score.
•    Among patients who were in endoscopic remission at one year of treatment in VIVID-1, 78.6% maintained endoscopic remission at two years as measured by SES-CD =4 and =2-point reduction from baseline, with no subscore >1 in any individual variable.

Additionally:

•    Among patients who were not in clinical remission by CDAI at one year, 60.8% gained clinical remission during the second year of treatment.
•    Among patients who were not in endoscopic remission at one year, 35.4% gained endoscopic remission during the second year of treatment.

In VIVID-2, the long-term safety profile of Omvoh in patients with moderately to severely active Crohn's disease was generally consistent with the known safety profile of Omvoh. During the second year of continuous treatment with Omvoh, 6.8% of patients with endoscopic response at one year reported a serious adverse event and 0.8% discontinued treatment due to an adverse event.

""Lilly is setting a high bar for sustained and durable treatment response for patients living with the profound impact of inflammatory bowel disease,"" said Mark Genovese, M.D., senior vice president of Lilly Immunology development. ""These results build on the body of evidence that demonstrates Omvoh's ability to provide early meaningful improvement and long-term disease control with strong clinical, endoscopic and histologic outcomes.""

Omvoh was approved by the United States Food and Drug Administration (FDA) for the treatment of moderately to severely active Crohn's disease in adults in January 2025. In December 2024, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Omvoh for the treatment of adults with moderately to severely active Crohn's disease. Lilly has submitted marketing applications around the globe, including in Canada, Japan and China, with additional global regulatory submissions planned. Omvoh is also approved in 44 countries for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

Omvoh is the first and only IL-23p19 antagonist to demonstrate long-term, multi-year, sustained efficacy and safety for both Crohn's disease and UC.

Omvoh has additional ongoing trials in Crohn's disease and UC, including studies to evaluate the long-term efficacy and safety of Omvoh in pediatric patients and adults, and a phase 4 real-world evidence study to evaluate Omvoh's impact in patients with UC in clinical practice.

VIVID-1 was a phase 3 randomized, double-blind, placebo-controlled 52-week study in adults with moderately to severely active Crohn's disease. Patients randomized to Omvoh received Omvoh 900mg by intravenous (IV) infusion at Week 0, Week 4 and Week 8 followed by a maintenance dose of 300mg by subcutaneous injection (SC) at Week 12 and then every 4 weeks (Q4W) for 40 weeks.

Participants who completed VIVID-1, including the Week 52 endoscopy, were eligible for VIVID-2. In VIVID-2, the primary objective is to evaluate the long-term e?ect of Omvoh in clinical remission by CDAI and endoscopic response at Week 52 of treatment in VIVID-2 (totaling 104 weeks of continuous treatment). Safety is being assessed from the ?rst dose in VIVID-2.

Using a modified non-responder imputation method, among Omvoh endoscopic responders at year one, 81.8% maintained endoscopic response at two years, 86.9% maintained clinical remission at two years, and 72.5% maintained endoscopic remission at two years.

Omvoh (mirikizumab-mkrz) is an interleukin-23p19 antagonist indicated for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults. Omvoh selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to over-activation of the IL-23 pathway plays a critical role in the pathogenesis of inflammatory bowel disease.

Omvoh and its delivery device base are trademarks owned by Eli Lilly and Company.

Lilly is a medicine company turning science into healing to make life better for people around the world. The company have been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!